Business Wire

MA-BATTERY-VENTURES

27.6.2024 13:01:33 CEST | Business Wire | Press release

Share
Harris-Koizumi Promoted to Partner, Searle to Principal at Battery Ventures

Battery Ventures, a global, technology-focused investment firm, today announced six new internal promotions across three offices, including the elevation of Satoshi Harris-Koizumi to partner and Collier Searle to principal.

Harris-Koizumi is based in New York and focuses on later-stage and majority software investments, mainly in the U.S. Since joining Battery 12 years ago, he has supported technology companies transforming industries ranging from hospitality to manufacturing to engineering and supply chain, among others.

Specifically, Harris-Koizumi has worked with exited Battery software companies Cambrio (a CAD/CAM specialist, acquired by Sandvik); HighJump (supply-chain tech, acquired by Accellos); Mendix (low-code platform technology, acquired by Siemens); and Olo (restaurant-ordering software, NYSE: OLO). He is currently involved with Battery’s investments in product-content software company 1WorldSync; developer-tools software firm AdaCore; club/member-management software company Clubessential Holdings; restaurant-software provider Crunchtime; translation-software company Smartling; and engineering-design software firm Tech Soft 3D. Harris-Koizumi, known as Toshi, holds a BA in economics from Dartmouth.

Searle, also based in New York, joined Battery in 2020 and focuses on late-stage and buyout investments in Europe and the U.S. She is involved with Battery’s investments in ORTEC, a company based in the Netherlands which provides decision-support software and data-science capabilities, and Shiftmove, a Berlin-based company providing “mobility-management” solutions to enterprises. Battery formed Shiftmove last year after acquiring two complementary, European fleet-management companies, Vimcar and Avrios. Before Battery, Searle worked at Apax Partners and Bank of America Merrill Lynch. She holds a BA in philosophy and political science from Middlebury.

“We are extremely excited to promote Toshi to partner and Collier to principal,” said Morad Elhafed, a Battery general partner who works closely with both investors. “Toshi has distinguished himself both by sourcing key deals for the firm—including Cambrio, Clubessential, Mendix and Tech Soft—and, later, serving as a trusted advisor to our portfolio executives and helping their companies scale. Similarly, Collier has done outstanding sourcing and advisory work, particularly as we increase our buyout activity in Europe. We are excited for both of them to continue their careers at Battery and add more value to the firm as we move into our fifth decade of investing.”

Battery also named two new vice presidents, Max Jessen and Stefan Momic, and two new associates, Jack McGuinness and Grace Hermes. Jessen and Momic are both based in Boston and work in Battery’s growing industrial technology and life-science tools practice. McGuinness, based in London, also focuses on industrial technology and life-science tools, while Hermes works in Battery’s New York office and focuses on later-stage software investments.

Earlier this year, Battery also announced the promotions of Aaron Neil to vice president and Luis-Luca de Haas to associate. In addition, Matt Penney was promoted to partner, information technology.

Battery Ventures provides investment advisory services solely to privately offered funds. Battery Ventures neither solicits nor makes its services available to the public or other advisory clients. For more information about Battery Ventures’ potential financing capabilities for prospective portfolio companies, please refer to our website. For a complete list of portfolio companies, please click here.

About Battery

Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627095034/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye